Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes

Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01895387

Enrollment

100

Registered

2013-07-10

Start date

2012-01-31

Completion date

2012-10-31

Last updated

2013-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Fasting Glucose, Newly Diagnosed Type 2 Diabetes

Brief summary

We determined the effects of dietary intervention (replacement of refined rice with whole grains and legumes and a high intake of vegetables) on circulating Lp-PLA2 activity and enzyme activity in peripheral blood mononuclear cells (PBMCs) in patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes.

Detailed description

Ninety-nine patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes were randomly assigned to either a control group (usual diet with refined rice) or the whole grain group.

Interventions

DIETARY_SUPPLEMENTDietary intervention-whole grains and legumes

Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.

DIETARY_SUPPLEMENTDietary intervention-Refined rice

Subjects in the control group maintained their usual diet of refined rice

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

39 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Subjects who were in in impaired fasting glucose (IFG, 100≤ fasting glucose \<126 mg/dL) * or newly diagnosed type 2 diabetes (fasting glucose ≥126 mg/dL)

Exclusion criteria

* current and/or past history of cardiovascular disease including angina * liver or kidney dysfunction * thyroid or pituitary disease * unstable weight loss/gain (≥2 kg) over the previous 12 months * pregnancy or lactation * taking medications or supplements

Design outcomes

Primary

Measure	Time frame
Plasma Lp-PLA2 activity	Change from baseline in Lp-PLA2 at 12 weeks

Secondary

Measure	Time frame
PBMC Lp-PLA2 activity	Change from baseline in PBMC Lp-PLA2 at 12 weeks

Other

Measure	Time frame
LDL particle size	Change from baseline in LDL particle size at 12 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026